Lyric Pharmaceuticals Holds Initial Close of Series A
March 02, 2015
Lyric Pharmaceuticals has held an initial close of $20.4 million for its Series A financing, co-led by RiverVest Venture Partners, Sante Ventures and Third Point Ventures. The clinical stage pharmaceutical company is developing therapeutics for gastrointestinal indications and in-licensed its initial development candidate in September. Capital from the financing will be used for two clinical studies and other supportive activities.